Nokia Co. (NYSE:NOK) had its price objective hosited by RBC Capital from $9.00 to $11.00 in a report released on Thursday. RBC Capital currently has an outperform rating on the stock.Nokia Corporation (ADR) (NYSE:NOK) shares after opening at $7.61 moved to $7.66 on last trade day and at the end of the day closed at $7.61. Company price to sales ratio in past twelve months was calculated as 1.64 and price to cash ratio as 2.26. Nokia Corporation (ADR) (NYSE:NOK) showed a negative weekly performance of -2.56%.
Pain Therapeutics (NASDAQ:PTIE) last released its earnings data on Tuesday, May 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.02. During the same quarter in the previous year, the company posted ($0.01) earnings per share. Analysts expect that Pain Therapeutics will post $-0.30 EPS for the current fiscal year.Pain Therapeutics, Inc. (NASDAQ:PTIE) shares fell -9.74% in last trading session and ended the day on $5.47. PTIE return on equity ratio is recorded as 92.70% and its return on assets is 56.10%. Pain Therapeutics, Inc. (NASDAQ:PTIE) yearly performance is 137.83%.
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research, Inc. (TSX: NRI) (together Mallickrodt) to settle a declaratory judgment action brought by IGI, concerning IGI’s filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015.IGI Laboratories, Inc. (NYSEMKT:IG) shares moved down -5.84% in last trading session and was closed at $5.00, while trading in range of $5.00-$5.28. IGI Laboratories, Inc. (NYSEMKT:IG) year to date performance is 63.93%.
Information Services Group (ISG) (NASDAQ: III), a leading technology insights, market intelligence and advisory services company, today named industry veteran Todd D. Lavieri partner and president of ISG Americas.Lavieri will oversee ISG’s largest region, representing about half of the firm’s revenues. He succeeds David J. Whitmore, who plans to return with his family to his native UK.Information Services Group, Inc. (NASDAQ:III) weekly performance is -1.23%. On last trading day company shares ended up $4.80. Information Services Group, Inc. (NASDAQ:III) distance from 50-day simple moving average is -3.01%. Analysts mean target price for the company is $6.25.
BioTelemetry (NASDAQ:BEAT) was downgraded by TheStreet from a “hold” rating to a “sell” rating in a research note issued on Tuesday.BioTelemetry, Inc. (NASDAQ:BEAT) shares after opening at $7.46 moved to $7.46 on last trade day and at the end of the day closed at $7.12. Company price to sales ratio in past twelve months was calculated as 1.40 and price to cash ratio as 15.66. BioTelemetry, Inc. (NASDAQ:BEAT) showed a negative weekly performance of -7.29%.
Leave a Reply